Acquired immunodeficiency syndrome (AIDS) is the most advanced stage of HIV infection, reached when the virus has damaged the immune system so severely that the body can no longer fight off infections and diseases it would normally handle easily. A person with HIV receives an AIDS diagnosis when their CD4 cell count drops below 200 cells per cubic millimeter of blood, or when they develop one of roughly two dozen specific illnesses known as AIDS-defining conditions. A healthy immune system typically maintains a CD4 count between 500 and 1,500.
How HIV Destroys the Immune System
HIV targets a specific type of white blood cell called a CD4 T-cell, sometimes called a “helper” cell because it coordinates the immune system’s response to threats. The virus latches onto the CD4 molecule on the cell’s surface, enters the cell, and hijacks its machinery to make copies of itself. This process kills the host cell, and the new virus particles go on to infect more CD4 cells.
The destruction happens through two distinct pathways. In cells that the virus successfully infects and replicates inside, the cell either bursts open or fuses with neighboring cells, spreading the infection further. But this accounts for only about 5% of overall CD4 cell loss. The remaining 95% of destruction happens through a more inflammatory process: when HIV tries to infect cells that resist replication, those cells die in a way that spills their contents into surrounding tissue. The released inflammatory signals then trigger the same type of death in nearby T-cells, creating a chain reaction that steadily erodes the immune system over time.
Each time the body’s memory T-cells (the cells that “remember” past infections) encounter HIV, they become targets for elimination. This progressive loss is what makes AIDS so dangerous. It’s not HIV itself that kills. It’s the collapse of immune defenses that leaves the body open to infections and cancers a functioning immune system would suppress.
How Long Progression Takes
Without treatment, chronic HIV infection typically advances to AIDS in 10 years or longer, though some people progress faster. The speed depends on factors like overall health, genetics, and the specific strain of HIV involved. During the years between initial infection and AIDS, a person may feel relatively well while their CD4 count gradually declines. This is why testing matters: many people don’t realize how much immune damage has accumulated until a serious illness appears.
What AIDS Looks Like
AIDS doesn’t have a single set of symptoms. Instead, it opens the door to a range of opportunistic infections and cancers that define the condition. The most common include a fungal lung infection called Pneumocystis pneumonia, a cancer called Kaposi sarcoma that causes dark skin lesions, severe and persistent yeast infections in the throat or lungs, tuberculosis that has spread beyond the lungs, and a brain infection caused by a parasite called toxoplasma.
Other hallmarks include chronic herpes sores lasting more than a month, a brain condition called HIV encephalopathy that affects thinking and coordination, severe and recurring bacterial pneumonia, and HIV wasting syndrome, which involves dramatic, unexplained weight loss with persistent diarrhea or fever. Certain cancers also qualify, including invasive cervical cancer, specific types of lymphoma, and primary brain lymphoma. The CDC recognizes over two dozen of these AIDS-defining conditions, and developing any one of them in the presence of HIV infection is enough for a diagnosis regardless of CD4 count.
Modern Treatment and Life Expectancy
Antiretroviral therapy has transformed AIDS from a death sentence into a manageable chronic condition for people with access to treatment. A 2023 analysis published in The Lancet, drawing on cohort data from Europe and North America, found that a 40-year-old man who started treatment after 2015 could expect to live an additional 37 years, reaching age 77. For women, the figure was 39 additional years. The general population figures for comparison were about 41 years for men and 46 for women. For people who maintained high CD4 counts on treatment, life expectancy was only a few years shorter than average.
Starting treatment late makes a significant difference. Women who began therapy with CD4 counts below 49 cells per cubic millimeter had roughly 25 additional years of life at age 40, compared to 39 years for those who started earlier. This gap underscores why early diagnosis and prompt treatment matter so much.
Transmission and “Undetectable = Untransmittable”
HIV spreads through specific body fluids: blood, semen, rectal fluids, vaginal fluids, and breast milk. The most common routes are unprotected sex and sharing needles. It does not spread through casual contact, saliva, sweat, or sharing food.
One of the most important developments in HIV science is the confirmation that effective treatment eliminates sexual transmission entirely. Multiple large studies tracking couples where one partner has HIV and the other does not found zero linked sexual transmissions when the HIV-positive partner maintained a viral load below 200 copies per milliliter. In the United States, “undetectable” is typically defined as fewer than 20 copies per milliliter. This principle, known as U=U (undetectable equals untransmittable), requires being on continuous antiretroviral therapy for at least six months before relying on it as a prevention measure.
Prevention Beyond Treatment
For people who don’t have HIV, pre-exposure prophylaxis (PrEP) reduces the risk of acquiring HIV through sex by up to 99% when taken consistently. PrEP is available as a daily pill or as a long-acting injection given every two months. In clinical trials, the injectable form showed 66% to 88% greater protection compared to daily pills, largely because it removes the challenge of remembering to take medication every day.
Post-exposure prophylaxis (PEP) is an emergency option for people who may have been exposed to HIV. It involves taking antiretroviral medication for 28 days, starting as soon as possible and within 72 hours of exposure. Condoms, sterile needles, and routine testing remain foundational prevention tools alongside these pharmaceutical options.
The Global Picture
AIDS-related deaths have dropped 56% since 2010, and new HIV infections have fallen 40% over the same period. But progress has stalled in some areas. In 2024, there were still 1.3 million new HIV infections worldwide, a number that barely changed from the prior year. UNAIDS modeling suggests that recent funding cuts to the global AIDS response could lead to an additional 6 million HIV infections and 4 million AIDS-related deaths by 2029 if not reversed. The tools to end AIDS as a public health threat exist. The gap is in reaching everyone who needs them.